Olson R D, MacDonald J S, vanBoxtel C J, Boerth R C, Harbison R D, Slonim A E, Freeman R W, Oates J A
J Pharmacol Exp Ther. 1980 Nov;215(2):450-4.
Adriamycin (ADR) has been shown to produce free radicals in NADPH microsomal systems, to increase oxygen consumption of both hepatic microsomes and heart sarcosomes and to stimulate superoxide formation in cardiac, submitochondria particles. These reactive products could produce the cardiotoxicity of ADR by oxidizing various membrane structures, especially if the heart lacks sufficient protective reducing substances such as thiols. We examined 1) the effect of ADR on reduced glutathione (G-SH) levels in various tissues including heart, 2) the ability of the sulfhydryl (SH) donor, cysteamine, to alter soluble SH levels in heart tissue after ADR administration and 3) the effects of SH donors (cysteamine and N-acetyl cysteine and G-SH depletion by diethyl maleate on ADR-induced lethality in Swiss ICR-HA mice. A single injection of ADR (15 mg/kg i.p.) elicited a statistically significant fall in liver (P < .05), heart (P < .02) and erythrocyte (P < .01) G-SH levels. Treatment with cysteamine protected against the fall in soluble SH groups in heart tissue. Cysteamine (50 mg/kg, i.p., every 8 hr for 6 days) or N-acetylcysteine (100 mg/kg, i.p., 1 hr before and 7 hr after ADR) protected against ADR-induced lethality and decreased the appearance of microscopic myocardial lesions. When endogenous levels of G-SH were depleted by diethyl maleate (300 mg/kg i.p., every 8 hr for 4 days), ADR lethality was markedly potentiated. Diethyl maleate alone did not cause death. We conclude 1) ADR significantly lowers G-SH levels in erythrocytes, liver and heart tissue, 2) the lowering of cardiac SH groups by ADR can be prevented by cysteamine and 3) ADR toxicity can be potentiated by diethyl maleate, a G-SH depletor, and reduced by cysteamine or N-acetyl cysteine, SH donors. These results suggest that the G-SH system may be involved in the modulation of ADR-induced toxicity.
阿霉素(ADR)已被证明在NADPH微粒体系统中产生自由基,增加肝微粒体和心脏肌粒的耗氧量,并刺激心脏亚线粒体颗粒中超氧化物的形成。这些活性产物可通过氧化各种膜结构产生ADR的心脏毒性,特别是如果心脏缺乏足够的保护性还原物质如硫醇时。我们研究了:1)ADR对包括心脏在内的各种组织中还原型谷胱甘肽(G-SH)水平的影响;2)巯基(SH)供体半胱胺改变ADR给药后心脏组织中可溶性SH水平的能力;3)SH供体(半胱胺和N-乙酰半胱氨酸)以及马来酸二乙酯对G-SH的消耗对瑞士ICR-HA小鼠ADR诱导致死率的影响。单次注射ADR(15mg/kg腹腔注射)导致肝脏(P<0.05)、心脏(P<0.02)和红细胞(P<0.01)中G-SH水平有统计学意义的下降。用半胱胺治疗可防止心脏组织中可溶性SH基团的下降。半胱胺(50mg/kg,腹腔注射,每8小时一次,共6天)或N-乙酰半胱氨酸(100mg/kg,腹腔注射,在ADR前1小时和后7小时)可防止ADR诱导的致死率,并减少显微镜下心肌损伤的出现。当用马来酸二乙酯(300mg/kg腹腔注射,每8小时一次,共4天)消耗内源性G-SH水平时,ADR致死率明显增强。单独使用马来酸二乙酯不会导致死亡。我们得出结论:1)ADR显著降低红细胞、肝脏和心脏组织中的G-SH水平;2)半胱胺可防止ADR降低心脏SH基团;3)G-SH消耗剂马来酸二乙酯可增强ADR毒性,而SH供体半胱胺或N-乙酰半胱氨酸可降低其毒性。这些结果表明G-SH系统可能参与了对ADR诱导毒性的调节。